4.7 Article

Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth

期刊

MOLECULAR THERAPY
卷 21, 期 1, 页码 101-108

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2012.161

关键词

-

资金

  1. NIH NCI [CA141150]
  2. NIH NINDS [NS037409]
  3. Forschungsgesellschaft for Brain Tumors
  4. EU-FP7-PEOPLE-2011-CIG
  5. Association for conduct of scientific research in the field of neonatology and pediatric intensive care: Unser Kind
  6. NATIONAL CANCER INSTITUTE [R01CA141150] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS037409, P50NS037409] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Microvesicles (MVs) play an important role in intercellular communication by carrying mRNAs, microRNAs (miRNAs), non-coding RNAs, proteins, and DNA from cell to cell. To our knowledge, this is the first report of delivery of a therapeutic mRNA/protein via MVs for treatment of cancer. We first generated genetically engineered MVs by expressing high levels of the suicide gene mRNA and protein-cytosine deaminase (CD) fused to uracil phosphoribosyltransferase (UPRT) in MV donor cells. MVs were isolated from these cells and used to treat pre-established nerve sheath tumors (schwannomas) in an orthotopic mouse model. We demonstrated that MV-mediated delivery of CD-UPRT mRNA/protein by direct injection into schwannomas led to regression of these tumors upon systemic treatment with the prodrug (5-fluorocytosine (5-FC)), which is converted within tumor cells to 5-fluorouracil (5-FU)-an anticancer agent. Taken together, these studies suggest that MVs can serve as novel cell-derived liposomes to effectively deliver therapeutic mRNA/proteins to treatment of diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据